Schrodinger Inc (SDGR)

$21.01 -0.70 (-3.22%)
Market Cap 1.54B
Revenue (ttm) 207.54M
Net Income (ttm) -187.12M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -90.16%
Debt to Equity Ratio 0.00
Volume 892,100
Avg Vol 1,146,232
Day's Range N/A - N/A
Shares Out 73.38M
Stochastic %K 50%
Beta 1.58
Analysts Strong Sell
Price Target $31.44

Company Profile

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through...

Industry: Health Information Services
Sector: Healthcare
Phone: 212 295 5800
Address:
1540 Broadway, 24th Floor, New York, United States
Cityhall
Cityhall Jul. 11 at 2:55 PM
$SDGR down again there it goes! Nothing seems to be there to stop it sinking deeper never to resurface again.
1 · Reply
Randall99
Randall99 Jul. 9 at 12:52 PM
$RVMD becoming an AI play with this partnership with iambic.ai? Similar to $SDGR Crossroads of oncology and tech
0 · Reply
JasonCO
JasonCO Jul. 7 at 8:43 PM
$SDGR nope
0 · Reply
ZacksResearch
ZacksResearch Jul. 7 at 3:23 PM
$RXRX down 22% YTD — Can it turn the tide? After shelving three drug candidates, RXRX focuses on promising REC-4881, showing a 43% reduction in polyp burden in early trials. More data expected in H2 2025, but competitive pressure from $RLAY and $SDGR, who also use AI-driven platforms, looms. Explore RXRX’s potential turnaround here 👉 https://www.zacks.com/commentary/2565928/will-rxrxs-shift-in-pipeline-focus-help-restore-investor-faith?cid=sm-stocktwits-2-2565928-body-850&ADID=SYND_STOCKTWITS_TWEET_2_2565928_BODY_850
0 · Reply
scott52
scott52 Jul. 2 at 4:13 PM
$SDGR Lagging big time.
0 · Reply
ZacksResearch
ZacksResearch Jul. 2 at 3:53 PM
$RXRX dips 24.1% YTD — facing competitive pressures in the TechBio space Despite its innovative RecursionOS platform and partnerships with Bayer and Roche, RXRX is underperforming the industry, sector, and S&P 500. Competitive pressure from $RLAY and $SDGR adds to the challenge. Discover the full story here 👉 https://www.zacks.com/commentary/2560564/can-rxrxs-ai-based-approach-revolutionize-the-drug-discovery-process?cid=sm-stocktwits-2-2560564-body-656&ADID=SYND_STOCKTWITS_TWEET_2_2560564_BODY_656
0 · Reply
shrwd
shrwd Jul. 1 at 6:06 PM
$SDGR Looks like a broadening wedge on lower TF. This one has me puzzled a bit. Guess I have more chart work to do. )
1 · Reply
shrwd
shrwd Jun. 28 at 11:13 AM
$SDGR
0 · Reply
StockHunter75
StockHunter75 Jun. 27 at 6:25 PM
$SDGR I was wrong, stopped out and going short now.
0 · Reply
StockAnalyticsAI
StockAnalyticsAI Jun. 26 at 7:40 PM
$SDGR Deep Dive https://youtu.be/ZDx9nPKmSu4?si=K_gl4fjpI5on7HE4
0 · Reply
Latest News on SDGR
Schrödinger Receives Fast Track Designation for SGR-1505 for the Treatment of Relapsed/Refractory Waldenström Macroglobulinemia

Jun 27, 2025, 8:00 AM EDT - 16 days ago

Schrödinger Receives Fast Track Designation for SGR-1505 for the Treatment of Relapsed/Refractory Waldenström Macroglobulinemia

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Jun 17, 2025, 8:30 AM EDT - 26 days ago

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Schrödinger: Assessing The Signal And The Noise In The Phase 1 Results

Jun 13, 2025, 1:02 PM EDT - 4 weeks ago

Schrödinger: Assessing The Signal And The Noise In The Phase 1 Results

Schrödinger Reports Encouraging Initial Phase 1 Clinical Data for SGR-1505 at EHA Annual Congress

Jun 12, 2025, 7:00 AM EDT - 4 weeks ago

Schrödinger Reports Encouraging Initial Phase 1 Clinical Data for SGR-1505 at EHA Annual Congress

Bronstein, Gewirtz & Grossman, LLC Encourages Schrödinger, Inc. (SDGR) Shareholders to Inquire about Securities Investigation

Jun 6, 2025, 10:00 AM EDT - 5 weeks ago

Bronstein, Gewirtz & Grossman, LLC Encourages Schrödinger, Inc. (SDGR) Shareholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Schrödinger, Inc. (SDGR) And Encourages Shareholders to Connect

Jun 5, 2025, 10:00 AM EDT - 5 weeks ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Schrödinger, Inc. (SDGR) And Encourages Shareholders to Connect

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Schrödinger, Inc. (SDGR) And Encourages Shareholders to Reach Out

Jun 4, 2025, 10:00 AM EDT - 5 weeks ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Schrödinger, Inc. (SDGR) And Encourages Shareholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Schrödinger, Inc. (SDGR) and Encourages Shareholders to Learn More About the Investigation

Jun 3, 2025, 10:00 AM EDT - 5 weeks ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Schrödinger, Inc. (SDGR) and Encourages Shareholders to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Encourages Schrödinger, Inc. (SDGR) Stockholders to Inquire about Securities Investigation

Jun 2, 2025, 10:00 AM EDT - 5 weeks ago

Bronstein, Gewirtz & Grossman, LLC Encourages Schrödinger, Inc. (SDGR) Stockholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Schrödinger, Inc. (SDGR) and Encourages Investors to Learn More About the Investigation

Jun 1, 2025, 10:00 AM EDT - 6 weeks ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Schrödinger, Inc. (SDGR) and Encourages Investors to Learn More About the Investigation

Schrödinger, Inc. (SDGR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

May 30, 2025, 10:00 AM EDT - 6 weeks ago

Schrödinger, Inc. (SDGR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Commercial Officer

May 29, 2025, 5:00 PM EDT - 6 weeks ago

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Commercial Officer

Bronstein, Gewirtz & Grossman, LLC Is Investigating Schrödinger, Inc. (SDGR) And Encourages Investors to Connect

May 29, 2025, 10:00 AM EDT - 6 weeks ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Schrödinger, Inc. (SDGR) And Encourages Investors to Connect

Schrödinger Expands Executive Leadership Team with Appointment of Mannix Aklian as Chief Commercial Officer, Global Head of Software Sales and Marketing

May 29, 2025, 8:00 AM EDT - 6 weeks ago

Schrödinger Expands Executive Leadership Team with Appointment of Mannix Aklian as Chief Commercial Officer, Global Head of Software Sales and Marketing

Jefferies' Michael Yee: Drug discovery could be one of the biggest beneficiaries of generative AI

May 28, 2025, 12:22 PM EDT - 6 weeks ago

Jefferies' Michael Yee: Drug discovery could be one of the biggest beneficiaries of generative AI

AMGN BIIB DHR GILD IBB ILMN NVS

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Schrödinger, Inc. (SDGR) And Encourages Stockholders to Reach Out

May 27, 2025, 10:00 AM EDT - 6 weeks ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Schrödinger, Inc. (SDGR) And Encourages Stockholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Is Investigating Schrödinger, Inc. (SDGR) And Encourages Stockholders to Connect

May 26, 2025, 10:00 AM EDT - 6 weeks ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Schrödinger, Inc. (SDGR) And Encourages Stockholders to Connect

Schrödinger, Inc. (SDGR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

May 25, 2025, 10:00 AM EDT - 7 weeks ago

Schrödinger, Inc. (SDGR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Schrödinger, Inc. (SDGR) and Encourages Stockholders to Learn More About the Investigation

May 23, 2025, 10:00 AM EDT - 7 weeks ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Schrödinger, Inc. (SDGR) and Encourages Stockholders to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Encourages Schrödinger, Inc. (SDGR) Investors to Inquire about Securities Investigation

May 22, 2025, 12:00 PM EDT - 7 weeks ago

Bronstein, Gewirtz & Grossman, LLC Encourages Schrödinger, Inc. (SDGR) Investors to Inquire about Securities Investigation

Schrödinger to Present at Jefferies Global Healthcare Conference

May 22, 2025, 8:30 AM EDT - 7 weeks ago

Schrödinger to Present at Jefferies Global Healthcare Conference

Schrödinger: Regulatory Tailwinds Are Supportive Of Continued Strong Growth (Rating Upgrade)

May 20, 2025, 11:37 PM EDT - 7 weeks ago

Schrödinger: Regulatory Tailwinds Are Supportive Of Continued Strong Growth (Rating Upgrade)

Schrödinger Announces CFO Appointment

May 20, 2025, 6:30 AM EDT - 7 weeks ago

Schrödinger Announces CFO Appointment

Schrödinger to Present Phase 1 Clinical Data on MALT1 Inhibitor SGR-1505 at EHA Annual Congress and International Conference on Malignant Lymphoma

May 14, 2025, 9:30 AM EDT - 2 months ago

Schrödinger to Present Phase 1 Clinical Data on MALT1 Inhibitor SGR-1505 at EHA Annual Congress and International Conference on Malignant Lymphoma

Schrödinger, Inc. (SDGR) Q1 2025 Earnings Call Transcript

May 7, 2025, 5:59 PM EDT - 2 months ago

Schrödinger, Inc. (SDGR) Q1 2025 Earnings Call Transcript

Schrödinger Reports Strong First Quarter 2025 Financial Results

May 7, 2025, 4:05 PM EDT - 2 months ago

Schrödinger Reports Strong First Quarter 2025 Financial Results

Schrödinger to Present at BofA Securities 2025 Healthcare Conference

May 5, 2025, 8:30 AM EDT - 2 months ago

Schrödinger to Present at BofA Securities 2025 Healthcare Conference

Schrödinger Presents New Preclinical Data at AACR Annual Meeting

Apr 28, 2025, 8:00 AM EDT - 2 months ago

Schrödinger Presents New Preclinical Data at AACR Annual Meeting

Schrödinger to Announce First Quarter 2025 Financial Results on May 7

Apr 23, 2025, 8:30 AM EDT - 2 months ago

Schrödinger to Announce First Quarter 2025 Financial Results on May 7

Schrödinger's Statement Regarding FDA Plan to Phase Out Animal Testing Requirement for Monoclonal Antibodies and Other Drugs

Apr 14, 2025, 8:00 AM EDT - 3 months ago

Schrödinger's Statement Regarding FDA Plan to Phase Out Animal Testing Requirement for Monoclonal Antibodies and Other Drugs

Schrödinger Poised For Growth As FDA Shifts Away From Animal Testing (Upgrade)

Apr 12, 2025, 10:26 AM EDT - 3 months ago

Schrödinger Poised For Growth As FDA Shifts Away From Animal Testing (Upgrade)

Schrödinger Expands Board of Directors with Appointment of Bridget van Kralingen

Mar 10, 2025, 8:30 AM EDT - 4 months ago

Schrödinger Expands Board of Directors with Appointment of Bridget van Kralingen

Schrödinger: Still Waiting On A Catalyst

Mar 2, 2025, 1:24 AM EST - 4 months ago

Schrödinger: Still Waiting On A Catalyst

Schrödinger, Inc. (SDGR) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 7:27 PM EST - 4 months ago

Schrödinger, Inc. (SDGR) Q4 2024 Earnings Call Transcript

Schrödinger Reports Strong Fourth Quarter and Full-Year 2024 Financial Results

Feb 26, 2025, 4:05 PM EST - 4 months ago

Schrödinger Reports Strong Fourth Quarter and Full-Year 2024 Financial Results

Schrödinger to Participate in Upcoming Investor Conferences

Feb 24, 2025, 8:30 AM EST - 4 months ago

Schrödinger to Participate in Upcoming Investor Conferences

Schrödinger to Announce Fourth Quarter and Full-Year 2024 Financial Results on February 26

Feb 12, 2025, 8:30 AM EST - 5 months ago

Schrödinger to Announce Fourth Quarter and Full-Year 2024 Financial Results on February 26

Schrödinger Provides Update on Progress Across the Business and Outlines 2025 Strategic Priorities

Jan 13, 2025, 7:00 AM EST - 6 months ago

Schrödinger Provides Update on Progress Across the Business and Outlines 2025 Strategic Priorities

Schrödinger Broadens and Accelerates Predictive Toxicology Initiative

Nov 18, 2024, 8:30 AM EST - 8 months ago

Schrödinger Broadens and Accelerates Predictive Toxicology Initiative

Schrödinger (SDGR) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 10:51 AM EST - 8 months ago

Schrödinger (SDGR) Q3 2024 Earnings Call Transcript

Schrödinger Reports Third Quarter 2024 Financial Results

Nov 12, 2024, 6:50 AM EST - 8 months ago

Schrödinger Reports Third Quarter 2024 Financial Results

Schrödinger to Present at Jefferies London Healthcare Conference

Nov 4, 2024, 8:30 AM EST - 8 months ago

Schrödinger to Present at Jefferies London Healthcare Conference

Schrödinger to Announce Third Quarter 2024 Financial Results on November 12

Oct 31, 2024, 8:30 AM EDT - 9 months ago

Schrödinger to Announce Third Quarter 2024 Financial Results on November 12

Schrödinger Presents SGR-3515 Preclinical Data at 2024 EORTC-NCI-AACR Symposium

Oct 23, 2024, 6:01 AM EDT - 9 months ago

Schrödinger Presents SGR-3515 Preclinical Data at 2024 EORTC-NCI-AACR Symposium

Schrödinger to Present New Preclinical SGR-3515 and PRMT5-MTA Data at 2024 EORTC-NCI-AACR Symposium

Oct 9, 2024, 6:06 AM EDT - 9 months ago

Schrödinger to Present New Preclinical SGR-3515 and PRMT5-MTA Data at 2024 EORTC-NCI-AACR Symposium

Kuehn Law Encourages Investors of Schrodinger, Inc. to Contact Law Firm

Sep 19, 2024, 2:18 PM EDT - 10 months ago

Kuehn Law Encourages Investors of Schrodinger, Inc. to Contact Law Firm

Cityhall
Cityhall Jul. 11 at 2:55 PM
$SDGR down again there it goes! Nothing seems to be there to stop it sinking deeper never to resurface again.
1 · Reply
Randall99
Randall99 Jul. 9 at 12:52 PM
$RVMD becoming an AI play with this partnership with iambic.ai? Similar to $SDGR Crossroads of oncology and tech
0 · Reply
JasonCO
JasonCO Jul. 7 at 8:43 PM
$SDGR nope
0 · Reply
ZacksResearch
ZacksResearch Jul. 7 at 3:23 PM
$RXRX down 22% YTD — Can it turn the tide? After shelving three drug candidates, RXRX focuses on promising REC-4881, showing a 43% reduction in polyp burden in early trials. More data expected in H2 2025, but competitive pressure from $RLAY and $SDGR, who also use AI-driven platforms, looms. Explore RXRX’s potential turnaround here 👉 https://www.zacks.com/commentary/2565928/will-rxrxs-shift-in-pipeline-focus-help-restore-investor-faith?cid=sm-stocktwits-2-2565928-body-850&ADID=SYND_STOCKTWITS_TWEET_2_2565928_BODY_850
0 · Reply
scott52
scott52 Jul. 2 at 4:13 PM
$SDGR Lagging big time.
0 · Reply
ZacksResearch
ZacksResearch Jul. 2 at 3:53 PM
$RXRX dips 24.1% YTD — facing competitive pressures in the TechBio space Despite its innovative RecursionOS platform and partnerships with Bayer and Roche, RXRX is underperforming the industry, sector, and S&P 500. Competitive pressure from $RLAY and $SDGR adds to the challenge. Discover the full story here 👉 https://www.zacks.com/commentary/2560564/can-rxrxs-ai-based-approach-revolutionize-the-drug-discovery-process?cid=sm-stocktwits-2-2560564-body-656&ADID=SYND_STOCKTWITS_TWEET_2_2560564_BODY_656
0 · Reply
shrwd
shrwd Jul. 1 at 6:06 PM
$SDGR Looks like a broadening wedge on lower TF. This one has me puzzled a bit. Guess I have more chart work to do. )
1 · Reply
shrwd
shrwd Jun. 28 at 11:13 AM
$SDGR
0 · Reply
StockHunter75
StockHunter75 Jun. 27 at 6:25 PM
$SDGR I was wrong, stopped out and going short now.
0 · Reply
StockAnalyticsAI
StockAnalyticsAI Jun. 26 at 7:40 PM
$SDGR Deep Dive https://youtu.be/ZDx9nPKmSu4?si=K_gl4fjpI5on7HE4
0 · Reply
Estimize
Estimize Jun. 23 at 9:03 PM
Wall St is expecting -0.83 EPS for $SDGR Q2 [Reporting 07/30 AMC] http://www.estimize.com/intro/sdgr?chart=historical&metric_name=eps&utm_c
0 · Reply
MikeyNJ
MikeyNJ Jun. 23 at 4:22 PM
$SDGR This stock is a gift that keeps giving. It's been tough to own, but has created a great opportunity to profit by selling put options. My June 17.5's went out worthless and today I added to my January 17.5's at $2.15. I will be happy to buy the stock at $15.35 if it gets put to me. I hold a very small position in the stock for the long term. But, selling these put options has been the way to profit here until it no longer works.
1 · Reply
scott52
scott52 Jun. 23 at 1:38 PM
$SDGR Powell's tenure is up in May 2026. Trump is clearly going to dump him and find a puppet to lower rates. I think the bio sector continues to be useless until spring 2026.
0 · Reply
Jasooon
Jasooon Jun. 23 at 2:47 AM
$SDGR chatGPT is correct or nah?
0 · Reply
Jasooon
Jasooon Jun. 23 at 2:47 AM
$SDGR 🚀 1. AI-Driven Review for Faster Drug Approvals • Makary is actively deploying AI tools (e.g., Elsa and a “cderGPT” initiative) across FDA centers to streamline and accelerate scientific review processes . • His goal: compress drug-approval timelines from ~10 months to as little as 1–2 months for “national priority” therapies , and even push for “instant” reviews in certain cases . Bull case link: An accelerated, AI-enabled FDA process favors companies like Schrödinger that generate AI/physics-powered data packages. Their computational platform can provide high-quality early evidence—positioning them as ideal beneficiaries of speedier review pathways.
0 · Reply
Jasooon
Jasooon Jun. 23 at 2:46 AM
$SDGR 🏷 2. “National Priority Vouchers” for Strategic Innovation • Makary’s “Commissioner’s National Priority Review Voucher” program will fast-track approvals for firms aligned with key public health goals—potentially including rare diseases, antibiotics, or affordability-driven innovation . • The targeted guidance encourages early data submission and real‑time FDA interaction . Bull case link: Schrödinger’s emerging clinical assets (like SGR-1505, -2921, -3515) could qualify for these vouchers. If they align with national priorities (e.g. rare disorders or oncology), they may gain an expedited approval path, boosting valuation and limiting development downside.
0 · Reply
Jasooon
Jasooon Jun. 23 at 2:45 AM
$SDGR 🧪 3. Replacing Animal Testing with AI & Human‑Relevant Models • Makary’s FDA is phasing out animal testing requirements (especially for mAbs) in favor of AI-based modeling and organ-on-a-chip methods . • This reflects a preference for computational chemistry and in-silico safety validation . Bull case link: Deeply in Schrödinger’s wheelhouse—their physics-based modeling platform can meet or exceed the FDA’s AI-driven, non-animal standards. That strengthens their role as a core R&D partner in later-stage validation and preclinical safety screening.
0 · Reply
JimmyBluechips
JimmyBluechips Jun. 22 at 8:08 PM
$SDGR the question looks like, how far do we overshoot the gap. I bet not too far
0 · Reply
scott52
scott52 Jun. 20 at 5:47 PM
$SDGR
0 · Reply
JimmyBluechips
JimmyBluechips Jun. 20 at 4:47 PM
$SDGR a dollar away from a legendary gap fill. So close
0 · Reply
StockHunter75
StockHunter75 Jun. 20 at 3:03 PM
$SDGR Dhorts getting greedy so we buy more. They will eventually cover or get burned.
0 · Reply
scott52
scott52 Jun. 18 at 4:16 PM
$SDGR Shareholders meeting today where Ramy and the board get to pretend like everything is going great. IPO in 2020. Came public at a $2.8B valuation. Today? $1.5B valuation. And shareholders have been massively diluted along the way. Meanwhile $100 invested in the SP in early 2020 would be worth $200 or so now. Some unfortunate changes in environment. Higher rates. The rise of Chinese bios and AI. More platforms doing what they do. But also just horrible management. So much promise. And very few tangible results. Maybe the next five years are better. But there's no reason to think so. Show me!
2 · Reply